{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:06:57Z","timestamp":1791295617223,"version":"4.1.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,7,15]],"date-time":"2014-07-15T00:00:00Z","timestamp":1405382400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1186\/s13045-014-0048-6","type":"journal-article","created":{"date-parts":[[2014,7,14]],"date-time":"2014-07-14T05:47:00Z","timestamp":1405316820000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["The mutation profile of JAK2 and CALR in Chinese Han patients with Philadelphia chromosome-negative myeloproliferative neoplasms"],"prefix":"10.1186","volume":"7","author":[{"given":"Zhiyuan","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinju","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihua","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shibao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaochao","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,7,15]]},"reference":[{"key":"48_CR1","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1182\/blood.V6.4.372.372","volume":"6","author":"W Dameshek","year":"1951","unstructured":"Dameshek W: Editorial: some speculations on the myeloproliferative syndromes. Blood. 1951, 6: 372-375.","journal-title":"Blood"},{"key":"48_CR2","first-page":"1497","volume":"132","author":"PC Nowell","year":"1960","unstructured":"Nowell PC: A minute chromosome in human chronic granulocytic leukemia. Science. 1960, 132: 1497.","journal-title":"Science"},{"key":"48_CR3","volume-title":"Who Classification Of Tumours Of Haematopoietic And Lymphoid Tissues","author":"S Swerdllow","year":"2008","unstructured":"Swerdllow S, Campo E, Harris NL: Who Classification Of Tumours Of Haematopoietic And Lymphoid Tissues. 2008, IARC Press, France"},{"key":"48_CR4","volume-title":"Dacie And Lewis Practical Haematology","author":"SM Lewis","year":"2006","unstructured":"Lewis SM, Bain BJ, Bates I, Dacie JV: Dacie And Lewis Practical Haematology. 2006, Elsevier Health Sciences, Philadelphia"},{"key":"48_CR5","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1038\/nature03546","volume":"434","author":"C James","year":"2005","unstructured":"James C, Ugo V, Le Cou\u00e9dic J-P, Staerk J, Delhommeau F, Lacout C, Gar\u00e7on L, Raslova H, Berger R, Bennaceur-Griscelli A: A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005, 434: 1144-1148. 10.1038\/nature03546.","journal-title":"Nature"},{"key":"48_CR6","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/S0140-6736(05)74230-6","volume":"365","author":"EJ Baxter","year":"2005","unstructured":"Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, Vassiliou GS, Bench AJ, Boyd EM, Curtin N: Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005, 365: 1054-1061. 10.1016\/S0140-6736(05)71142-9.","journal-title":"Lancet"},{"key":"48_CR7","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1056\/NEJMoa065202","volume":"356","author":"LM Scott","year":"2007","unstructured":"Scott LM, Tong W, Levine RL, Scott MA, Beer PA, Stratton MR, Futreal PA, Erber WN, McMullin MF, Harrison CN: JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med. 2007, 356: 459-468. 10.1056\/NEJMoa065202.","journal-title":"N Engl J Med"},{"key":"48_CR8","doi-asserted-by":"publisher","first-page":"e270","DOI":"10.1371\/journal.pmed.0030270","volume":"3","author":"Y Pikman","year":"2006","unstructured":"Pikman Y, Lee BH, Mercher T, McDowell E, Ebert BL, Gozo M, Cuker A, Wernig G, Moore S, Galinsky I: MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 2006, 3: e270-10.1371\/journal.pmed.0030270.","journal-title":"PLoS Med"},{"key":"48_CR9","doi-asserted-by":"publisher","first-page":"3472","DOI":"10.1182\/blood-2006-04-018879","volume":"108","author":"AD Pardanani","year":"2006","unstructured":"Pardanani AD, Levine RL, Lasho T, Pikman Y, Mesa RA, Wadleigh M, Steensma DP, Elliott MA, Wolanskyj AP, Hogan WJ: MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood. 2006, 108: 3472-3476. 10.1182\/blood-2006-04-018879.","journal-title":"Blood"},{"key":"48_CR10","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/sj.leu.2404955","volume":"22","author":"A Tefferi","year":"2008","unstructured":"Tefferi A, Vardiman J: Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia. 2008, 22: 14-22. 10.1038\/sj.leu.2404955.","journal-title":"Leukemia"},{"key":"48_CR11","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","volume":"369","author":"T Klampfl","year":"2013","unstructured":"Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD, Them NC, Berg T, Gisslinger B, Pietra D: Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013, 369: 2379-2390. 10.1056\/NEJMoa1311347.","journal-title":"N Engl J Med"},{"key":"48_CR12","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","volume":"369","author":"J Nangalia","year":"2013","unstructured":"Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC, Avezov E, Li J, Kollmann K, Kent DG: Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013, 369: 2391-2405. 10.1056\/NEJMoa1312542.","journal-title":"N Engl J Med"},{"key":"48_CR13","first-page":"\u115f","volume":"\u115f","author":"A Tefferi","year":"2014","unstructured":"Tefferi A, Thiele J, Vannucchi A, Barbui T: An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms. Leukemia. 2014, \u115f: \u115f-[Epub ahead of print]","journal-title":"Leukemia"},{"key":"48_CR14","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/nrclinonc.2014.16","volume":"11","author":"A Tefferi","year":"2014","unstructured":"Tefferi A, Pardanani A: Genetics: CALR mutations and a new diagnostic algorithm for MPN. Nat Rev Clin Oncol. 2014, 11: 125-126. 10.1038\/nrclinonc.2014.16.","journal-title":"Nat Rev Clin Oncol"},{"key":"48_CR15","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","volume":"7","author":"RL Levine","year":"2005","unstructured":"Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, Boggon TJ, Wlodarska I, Clark JJ, Moore S: Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005, 7: 387-397. 10.1016\/j.ccr.2005.03.023.","journal-title":"Cancer Cell"},{"key":"48_CR16","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.3324\/haematol.12883","volume":"93","author":"AV Jones","year":"2008","unstructured":"Jones AV, Cross NC, White HE, Green AR, Scott LM: Rapid identification of JAK2 exon 12 mutations using high resolution melting analysis. Haematologica. 2008, 93: 1560-1564. 10.3324\/haematol.12883.","journal-title":"Haematologica"},{"key":"48_CR17","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.3324\/haematol.13074","volume":"93","author":"A Theocharides","year":"2008","unstructured":"Theocharides A, Passweg JR, Medinger M, Looser R, Li S, Hao-Shen H, Buser AS, Gratwohl A, Tichelli A, Skoda RC: The allele burden of JAK2 mutations remains stable over several years in patients with myeloproliferative disorders. Haematologica. 2008, 93: 1890-1893. 10.3324\/haematol.13074.","journal-title":"Haematologica"},{"key":"48_CR18","doi-asserted-by":"publisher","first-page":"e26534","DOI":"10.1371\/journal.pone.0026534","volume":"6","author":"Z Wu","year":"2011","unstructured":"Wu Z, Yuan H, Zhang X, Liu W, Xu J, Zhang W, Guan M: Development and inter-laboratory validation of unlabeled probe melting curve analysis for detection of JAK2 V617F mutation in polycythemia vera. PLoS One. 2011, 6: e26534-10.1371\/journal.pone.0026534.","journal-title":"PLoS One"},{"key":"48_CR19","doi-asserted-by":"publisher","first-page":"435","DOI":"10.2353\/jmoldx.2008.080015","volume":"10","author":"A Pancrazzi","year":"2008","unstructured":"Pancrazzi A, Guglielmelli P, Ponziani V, Bergamaschi G, Bosi A, Barosi G, Vannucchi AM: A sensitive detection method for MPL W515L or MPL W515K mutation in chronic myeloproliferative disorders with locked nucleic acid-modified probes and real-time polymerase chain reaction. J Mol Diagn. 2008, 10: 435-441. 10.2353\/jmoldx.2008.080015.","journal-title":"J Mol Diagn"},{"key":"48_CR20","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1182\/blood-2007-07-101576","volume":"111","author":"D Pietra","year":"2008","unstructured":"Pietra D, Li S, Brisci A, Passamonti F, Rumi E, Theocharides A, Ferrari M, Gisslinger H, Kralovics R, Cremonesi L: Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders. Blood. 2008, 111: 1686-1689. 10.1182\/blood-2007-07-101576.","journal-title":"Blood"},{"key":"48_CR21","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1182\/blood-2008-01-135897","volume":"112","author":"AM Vannucchi","year":"2008","unstructured":"Vannucchi AM, Antonioli E, Guglielmelli P, Pancrazzi A, Guerini V, Barosi G, Ruggeri M, Specchia G, Lo-Coco F, Delaini F: Characteristics and clinical correlates of MPL 515W> L\/K mutation in essential thrombocythemia. Blood. 2008, 112: 844-847. 10.1182\/blood-2008-01-135897.","journal-title":"Blood"},{"key":"48_CR22","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1182\/blood-2008-01-131664","volume":"112","author":"PA Beer","year":"2008","unstructured":"Beer PA, Campbell PJ, Scott LM, Bench AJ, Erber WN, Bareford D, Wilkins BS, Reilly JT, Hasselbalch HC, Bowman R: MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. Blood. 2008, 112: 141-149. 10.1182\/blood-2008-01-131664.","journal-title":"Blood"},{"key":"48_CR23","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1182\/blood-2006-01-013540","volume":"108","author":"E Lippert","year":"2006","unstructured":"Lippert E, Boissinot M, Kralovics R, Girodon F, Dobo I, Praloran V, Boiret-Dupr\u00e9 N, Skoda RC, Hermouet S: The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera. Blood. 2006, 108: 1865-1867. 10.1182\/blood-2006-01-013540.","journal-title":"Blood"},{"key":"48_CR24","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1038\/leu.2010.148","volume":"24","author":"F Passamonti","year":"2010","unstructured":"Passamonti F, Rumi E, Pietra D, Elena C, Boveri E, Arcaini L, Roncoroni E, Astori C, Merli M, Boggi S: A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. Leukemia. 2010, 24: 1574-1579. 10.1038\/leu.2010.148.","journal-title":"Leukemia"},{"key":"48_CR25","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1038\/sj.leu.2404810","volume":"21","author":"A Pardanani","year":"2007","unstructured":"Pardanani A, Lasho T, Finke C, Hanson C, Tefferi A: Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera. Leukemia. 2007, 21: 1960-1963. 10.1038\/sj.leu.2404810.","journal-title":"Leukemia"},{"key":"48_CR26","doi-asserted-by":"publisher","first-page":"2813","DOI":"10.1182\/blood-2010-11-316810","volume":"117","author":"F Passamonti","year":"2011","unstructured":"Passamonti F, Elena C, Schnittger S, Skoda RC, Green AR, Girodon F, Kiladjian J-J, McMullin MF, Ruggeri M, Besses C: Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations. Blood. 2011, 117: 2813-2816. 10.1182\/blood-2010-11-316810.","journal-title":"Blood"},{"key":"48_CR27","doi-asserted-by":"publisher","first-page":"567","DOI":"10.3343\/kjlm.2010.30.6.567","volume":"30","author":"JT Kim","year":"2010","unstructured":"Kim JT, Cho YG, Choi SI, Lee YJ, Kim HR, Jang SJ, Moon DS, Park YJ, Park G: JAK2 V617F and Exon 12 Genetic Variations in Korean Patients with BCR\/ABL1-negative Myeloproliferative Neoplasms. Korean J Lab Med. 2010, 30: 567-574. 10.3343\/kjlm.2010.30.6.567.","journal-title":"Korean J Lab Med"},{"key":"48_CR28","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1093\/jjco\/hyp048","volume":"39","author":"JH Ohyashiki","year":"2009","unstructured":"Ohyashiki JH, Hisatomi H, Shimizu S, Sugaya M, Ohyashiki K: Detection of low allele burden of JAK2 exon 12 mutations using TA-cloning in patients with erythrocytosis. Jpn J Clin Oncol. 2009, 39: 509-513. 10.1093\/jjco\/hyp048.","journal-title":"Jpn J Clin Oncol"},{"key":"48_CR29","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1309\/AJCPK7KGOWPHYWM0","volume":"134","author":"Y-M Yeh","year":"2010","unstructured":"Yeh Y-M, Chen Y-L, Cheng H-Y, Su W-C, Chow N-H, Chen T-Y, Ho C-L: High percentage of JAK2 exon 12 mutation in Asian patients with polycythemia vera. Am J Clin Pathol. 2010, 134: 266-270. 10.1309\/AJCPK7KGOWPHYWM0.","journal-title":"Am J Clin Pathol"},{"key":"48_CR30","doi-asserted-by":"publisher","first-page":"414","DOI":"10.3324\/haematol.13223","volume":"94","author":"S Schnittger","year":"2009","unstructured":"Schnittger S, Bacher U, Haferlach C, Geer T, M\u00fcller P, Mitterm\u00fcller J, Petrides P, Schlag R, Sandner R, Selbach J: Detection of JAK2 exon 12 mutations in 15 patients with JAK2V617F negative polycythemia vera. Haematologica. 2009, 94: 414-418. 10.3324\/haematol.13223.","journal-title":"Haematologica"},{"key":"48_CR31","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1182\/blood-2014-01-550434","volume":"123","author":"E Rumi","year":"2014","unstructured":"Rumi E, Harutyunyan AS, Pietra D, Milosevic JD, Casetti IC, Bellini M, Them NC, Cavalloni C, Ferretti VV, Milanesi C: CALR exon 9 mutations are somatically acquired events in familial cases of essential thrombocythemia or primary myelofibrosis. Blood. 2014, 123: 2416-2419. 10.1182\/blood-2014-01-550434.","journal-title":"Blood"},{"key":"48_CR32","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1182\/blood-2013-11-537167","volume":"123","author":"P Lundberg","year":"2014","unstructured":"Lundberg P, Karow A, Nienhold R, Looser R, Hao-Shen H, Nissen I, Girsberger S, Lehmann T, Passweg J, Stern M: Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. Blood. 2014, 123: 2220-2228. 10.1182\/blood-2013-11-537167.","journal-title":"Blood"},{"key":"48_CR33","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1038\/leu.2009.47","volume":"23","author":"A Tefferi","year":"2009","unstructured":"Tefferi A, Pardanani A, Lim K, Abdel-Wahab O, Lasho T, Patel J, Gangat N, Finke C, Schwager S, Mullally A: TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia. 2009, 23: 905-911. 10.1038\/leu.2009.47.","journal-title":"Leukemia"},{"key":"48_CR34","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1038\/leu.2010.69","volume":"24","author":"A Tefferi","year":"2010","unstructured":"Tefferi A: Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia. 2010, 24: 1128-1138. 10.1038\/leu.2010.69.","journal-title":"Leukemia"},{"key":"48_CR35","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1038\/leu.2011.77","volume":"25","author":"F Stegelmann","year":"2011","unstructured":"Stegelmann F, Bullinger L, Schlenk R, Paschka P, Griesshammer M, Blersch C, Kuhn S, Schauer S, D\u00f6hner H, D\u00f6hner K: DNMT3A mutations in myeloproliferative neoplasms. Leukemia. 2011, 25: 1217-1219. 10.1038\/leu.2011.77.","journal-title":"Leukemia"},{"key":"48_CR36","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1002\/gcc.21960","volume":"51","author":"M Brecqueville","year":"2012","unstructured":"Brecqueville M, Rey J, Bertucci F, Coppin E, Finetti P, Carbuccia N, Cervera N, Gelsi\u2010Boyer V, Arnoulet C, Gisserot O: Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasms. Genes Chromosomes Cancer. 2012, 51: 743-755. 10.1002\/gcc.21960.","journal-title":"Genes Chromosomes Cancer"},{"key":"48_CR37","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1038\/leu.2013.85","volume":"27","author":"I Vorechovsky","year":"2013","unstructured":"Vorechovsky I, Jones A, Cross N: Why do we see JAK2 exon 12 mutations in myeloproliferative neoplasms&quest. Leukemia. 2013, 27: 1930-1932. 10.1038\/leu.2013.85.","journal-title":"Leukemia"},{"key":"48_CR38","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1182\/blood-2013-11-538983","volume":"123","author":"G Rotunno","year":"2014","unstructured":"Rotunno G, Mannarelli C, Guglielmelli P, Pacilli A, Pancrazzi A, Pieri L, Fanelli T, Bosi A, Vannucchi AM: Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. Blood. 2014, 123: 1552-1555.","journal-title":"Blood"},{"key":"48_CR39","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1182\/blood-2013-11-539098","volume":"123","author":"E Rumi","year":"2014","unstructured":"Rumi E, Pietra D, Ferretti V, Klampfl T, Harutyunyan AS, Milosevic JD, Them NC, Berg T, Elena C, Casetti IC: JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood. 2014, 123: 1544-1551. 10.1182\/blood-2014-01-550434.","journal-title":"Blood"},{"key":"48_CR40","first-page":"\u115f","volume":"\u115f","author":"A Tefferi","year":"2014","unstructured":"Tefferi A, Wassie E, Lasho T, Finke C, Belachew A, Ketterling R, Hanson C, Pardanani A, Gangat N, Wolanskyj A: Calreticulin mutations and long-term survival in essential thrombocythemia. Leukemia. 2014, \u115f: \u115f-[Epub ahead of print]","journal-title":"Leukemia"},{"key":"48_CR41","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1586\/17474086.2014.876898","volume":"7","author":"U Gianelli","year":"2014","unstructured":"Gianelli U, Iurlo A, Cattaneo D, Lambertenghi-Deliliers G: Cooperation between pathologists and clinicians allows a better diagnosis of Philadelphia chromosome-negative myeloproliferative neoplasms. Expert Rev Hematol. 2014, 7: 255-264. 10.1586\/17474086.2014.876898.","journal-title":"Expert Rev Hematol"}],"container-title":["Journal of Hematology & Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-014-0048-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13045-014-0048-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-014-0048-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-014-0048-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T00:42:25Z","timestamp":1630543345000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-014-0048-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7,15]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["48"],"URL":"https:\/\/doi.org\/10.1186\/s13045-014-0048-6","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,7,15]]},"assertion":[{"value":"1 May 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"48"}}